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Background: Apolipoprotein M (apoM), as a novel apolipoprotein which is mainly expressed in liver and kidney
tissues, is associated with development and progression of atherosclerosis and diabetes. Our group have recently
shown that Dihydrocapsaicin(DHC)can significantly decrease atherosclerotic plaque formation in apoE−/− mice.
However, the effect and possible mechanism of DHC on apoM expression remain unclear.
Methods: HepG2 cells were treated with 0 μM, 25 μM, 50 μM and 100 μM DHC for 24 h or were treated with
100 μM DHC for 0, 6, 12, and 24 h, respectively. The mRNA levels and protein levels were measured by real-time
quantitative PCR and western blot analysis, respectively.
Results: We found that DHC markedly decreased expression of apoM at both mRNA and protein level in HepG2
cells in a dose-dependent and time-dependent manner. Expression of Foxa2 was decreased while expression of
LXRα was increased by DHC treatment in HepG2 cells. In addittion, overexpression of Foxa2 markedly compensated
the inhibition effect induced by DHC on apoM expression. LXRα small interfering RNA significantly abolished the
inhibition effect which induced by DHC on apoM expression. The liver of C57BL/6 mice treated with DHC had
significantly lower expression of apoM. Furthermore, the liver had lower expression of Foxa2 while had higher
expression of LXRα.
Conclusions: DHC could down-regulate apoM expression through inhibiting Foxa2 expression and enhancing LXRα
expression in HepG2 cells.
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Capsaicinoids, including capsaicin and dihydrocapsaicin
(DHC), which together typically represent 85–90% of
the total capsaicinoid content in ‘hot chilli peppers’ ex-
tract, and its minor components include nordihydrocap-
saicin, homocapsaicin and homodihydrocapsaicin [1,2].
These spice principles have been proved to augment
carbohydrate metabolism [3,4], energy expenditure [5]
and lipid metabolism [6-8] in rodents and/or humans,
and have been successfully used in the treatment of* Correspondence: nfyyzl@163.com; nfyywangqian@163.com
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unless otherwise stated.diverse clinical conditions such as relief the pain of per-
ipheral neuropathies, sympomatic treatment of rheuma-
toid arthritis and osteoarthritis [9]. Previous studies have
demonstrated that regular consumption of chilli in-
creases the resistance of oxidation of serum lipoproteins
in vitro [6] and attenuate postprandial hyperinsulinemia
[10], actions that may help in reducing cardiovascular
diseases (CVD) risk. Adams et al. have demonstrated
that capsaicin and DHC could inhibit in vitro platelet ag-
gregation and the activity of clotting factors VIII and IX,
a property which may contribute to the prevention of
the onset and/or treatment of CVD [11]. Furthermore,
our group have recently shown that DHC can signifi-
cantly decrease atherosclerotic plaque formation involv-
ing in a PPARγ/LXRα pathway in apoE−/− mice fed atd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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the notion that capsaicinoids associate with CVD, such
as atherosclerosis and coronary heart disease in
particular.
Apolipoprotein M (apoM) was first described by Xu and
Dahlbäck in 1999 [12]. ApoM is a member of the lipocalin
protein superfamily, whose members exhibit diverse prop-
erties such as lipid binding, transport, and immunological
functions [13,14]. ApoM, mainly expressed in hepatocytes
and in the tubular epithelial cells of the kidney, is mainly
associated to HDL (96% is bound to HDL), but also binds
to low density lipoprotein (LDL), very low density lipopro-
tein (VLDL) and chylomicrons [12,15-17]. It has been
proved that apoM plays an important role in formation of
pre-β-HDL and cholesterol efflux to HDL, which further
influences the HDL cholesterol concentration in plasma.
Moreover, the silencing of apoM expression was associated
with the absence of pre-β-HDL particles in plasma [18]. In
addition, plasma apoM is modestly reduced in patients with
diabetes compared to controls [19]. Futhermore, Serum
apoM concentrations and hepatic APOM mRNA levels
were significantly reduced in the hyperglycemic rats, indi-
cating that the low expression levels of apoM in these dia-
betic animals could be ascribed to hyperglycemia [20].
These observations support the notion that apoM is linked
to cholesterol metabolism and diabetes.
FOXA genes, formerly termed HNF3 (hepatocyte nu-
clear factors), is transcription factor involved in glucose
homeostasis and lipid metabolism in liver [21,22]. Foxa2
is phosphorylated and excluded from the nucleus when
plasma insulin levels increase [23]. A binding site for
Foxa2 in the APOM promoter is at position −474. It had
been proved that obese mice had decreased apoM ex-
pression and plasma pre-β-HDL levels due to inactiva-
tion of Foxa2 in the hyperinsulinemic state. Treatment
wild-type mice and ob/ob mice with an adenovirus con-
taining phosphorylation-defective Foxa2 not only im-
proved glucose and lipid homeostasis but also increased
hepatic apoM mRNA expression. In contrast, haploin-
sufficient Foxa2+/−mice exhibited decreases in hepatic
apoM expression and in plasma pre-β-HDL and HDL
levels [24]. Together, these results suggest that Foxa2
regulates APOM transcription.
Liver X Receptor α (LXRα) is a major transcriptional
regulator of cholesterol homeostasis and also regulates
lipid and glucose metabolism [25,26]. LXRα is more re-
stricted and mainly found in liver, intestine, fat tissue,
macrophages, kidney and gonads, suggesting their im-
portant function in the control of cholesterol homeosta-
sis, whereas LXRβ is expressed in most cell types [27].
Zhang et al. demonstrated that LXR agonist, TO901317,
could decrease hepatic apoM expression in the vivo and
in vitro. They showed that serum apoM of mice treated
with 100 mg/kg/d of TO901317 decreased significantlyas compared to control mice. In cultured HepG2 cells,
TO901317 caused a downregulation of apoM expression,
indicating that apoM is another target gene of LXR. The
combination of 9-cis-retinoic acid (RA) and T0901317
showed additive effects, which suggests that apoM ex-
pression is modulated by the LXR/RXR pathway [28].
However, the relation between the DHC and apoM in
HepG2 cells remain unclear. whether Foxa2 and LXRα-
dependent pathway involving in this progress has not
yet been explored. In the present study, we demon-
strated that DHC could markedly down-regulate apoM
expression through inhibiting Foxa2 expression and en-




thyl]-8-methyl-6-nonanamide) was purchased from Sigma
Chemical Company (St. Louis, MO, USA). The PrimeScript
RT Reagent Kit (Perfect Real Time) (DRR037A) (TaKaRa,
Japan), SYBR Premix Ex TaqTM II (Tli RNaseH Plus)
(DRR820A) (TaKaRa,Japan) were obtained as indicated. All
other chemicals were of the best grade available from com-
mercial sources.
Animals
Eight-week-old, female C57BL/6 mice (Laboratory Animal
Center of Peking University, Beijing, China) with a mean
body mass of 20 g were randomly divided into two groups
(n = 5/group): (1) Control group were treated with
cholesterol-free vegetable oil by oral gavage (0.2 mL per
mouse) for one week. (2) DHC group were treated with
cholesterol-free vegetable oil containing DHC (3.0 mg/kg
body weight) daily by oral gavage(0.2 mL per mouse) for
one week. All animals were housed five per cage at 25°C
on a 12-h/12-h light/dark cycle with unlimited access to
chow and water. The animal procedures were approved by
the Animal Experimental Committee at Nanfang Hospital
(Guangdong, China).
Cell culture
Human hepatocytes (HepG2) was purchased from the
American Type Culture Collection(ATCC, Manassas,
VA, USA). The HepG2 cells were grown in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with
10% fetal calf serum (FCS) and 1% penicillin/strepto-
mycin. Cells were incubated at 37°C in an atmosphere of
5% CO2. Cells were seeded in 6-or12-well plates or 60-
mm dishes and grown to 60%–80% confluence before
use.
Chemicals
DHC was initially dissolved in 100% ethanol to make a
stock solution of 1 mol/L and then diluted for further
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centration of the dilutions was 0.1%. Normal buffered saline
containing 0.1% ethanol was used as the solvent in the con-
trol cells. Dilutions were prepared from stock solutions
shortly before the experiment.
RNA isolation and real-time quantitative PCR analysis
(qPCR)
Total RNA from mouse tissues or cultured cells was ex-
tracted using TRIzol reagent (Invitrogen) according to
the manufacturer’s instructions. Real-time quantitative
PCR, using SYBR Green detection chemistry, was per-
formed on an ABI 7500 Fast Real Time PCR system
(Applied Biosystems, Foster City, CA, USA). The follow-
ing primers were used: apoM forward, 5′-CTGAATGA-
GACAGGCCAGGGTTA-3′; apoM reverse, 5′-CAGGTC
AGTTATTGGACAG CTCACA-3′; Foxa2 forward, 5′-
CGTCCGACTGGAGCAGCTACTAT-3′; Foxa2 reverse,
5′-AT GTACGTGTTCATGCCGTTCA-3′; LXRα for-
ward, 5′-TCTGGAGACATCTCGGAGGTAC AAC-3′;
LXRα reverse, 5′-AGCAAGGCAAACTCGGCATC-3′;
GAPDH forward, 5′-GACT CATGACCACAGTCCATG
C-3′; GAPDH reverse, 3′-AGAGGCAGGGATGATGTT
CTG-5′. Melt curve analyses of all real-time PCR prod-
ucts were performed and shown to produce a single
DNA duplex. All samples were measured in triplicate
and the mean value was considered for comparative ana-
lysis. Quantitative measurements were determined using
the △△Ct method and GAPDH expression was used as
the internal control.
Western blot analyses
Proteins were extracted from mouse tissues or cultured
cells using RIPA buffer (Biocolor Ltd., Belfast, Northern
Ireland, UK), quantified using the BCA protein assay kit
(KeyGen Biotechnologies, Nanjing, China), and then sub-
jected to western blot analyses (10% sodium dodecyl sul-
fate–polyacrylamide gel electrophoresis; 30 μg protein
per lane) using rabbit polyclonal anti-APOM antibodies
(BD Bio-sciences, San Jose, CA, USA), rabbit polyclonal
anti-Foxa2 antibodies (Epitomics., CA, USA), and rabbit
polyclonal anti-LXRα (Proteintech group, Inc., Chicago,
IL, USA) and β-actin-specific antibodies (Abcam Inc.,
Cambridge, MA, USA). The proteins were visualized
using a chemiluminescence method (ECL Plus Western
Blot Detection System; Amerisham Biosciences, Foster
City, CA, USA).
Transfection with small interfering RNA (siRNA)
The siRNAs against Foxa2 and LXRα and an irrelevant
21-nucleotide control siRNA (Negative Control) were
purchased from Ribo Biotechnology. Cells (2 × 106 cells/
well) were transfected using Lipofectamine2000 transfec-
tion reagent for 48 h according to the manufacturer’sinstructions. After 48 h of transfection, real-time RT-
PCR and western blotting were performed.
Construction of recombinant plasmids
The PIRES2-EGFP and PCR-XL-TOPO vectors (containing
Foxa2 or LXRα which was assembled by the chemically
synthesized oligos through PCR) were purchased from
Invitrogen. Segments of EcoRI-Foxa2 or LXRα and IRES-
EGFP-XhoI were amplified using the template of the
PCR-XL-TOPO and PIRES2-EGFP vectors, respectively.
EcoRI-Foxa2-IRES-EGFP-XhoI or EcoRI- LXRα-IRES-
EGFP-XhoI was joined by the two above-mentioned
segments using overlap PCR. Gel electrophoresis was per-
formed and the relevant band was excised from the gel,
double enzyme-digested by EcoRI/XhoI, incorporated into
the pcDNA3.1(+) vector, and then transformed into compe-
tent E.coli DH5a cells for further amplification and use.
The recombinant plasmids were verified by sequencing
and named pcDNA3.1-Foxa2 and pcDNA3.1-LXRα. The
plasmid transfection process was performed using Lipofec-
tamine 2000 transfection reagent according to the manu-
facturer’s instructions.
Statistical analyses
Data are reported as means ± S.D. The date were com-
pared by one-way analysis of variance and the Student’s
t-test, using the Statistical Package for the Social Sci-
ences (version13.0) software (SPSS, Inc., Chicago, IL,
USA). Statistical significance was obtained when p values
were less than 0.05.
Results
DHC down-regulates apoM expression in HepG2 cells
ApoM is highly expressed in the liver and kidney in
humans, mice, and pigs. In the liver, apoM is expressed
in hepatocytes and mainly secreted into the plasma,
where it becomes integrated in plasma lipoproteins. We
first examined the effect of DHC on apoM expression in
HepG2 cells by real-time quantitative PCR and Western
blot assays. As shown, DHC obviously decreased apoM
expression at both transcriptional levels and translational
levels in a dose-dependent (Figure 1A and B) and time-
dependent manner (Figure 1C and D).
Foxa2 is involved in DHC-induced down-regulation of
apoM in HepG2 cells
Previously researches revealed that apoM expression is
directly regulated by Foxa2, which is a transcription fac-
tor involved in hepatic development via the regulation of
glucose homeostasis in liver. We next explore whether
Foxa2 expression can be affected by DHC in HepG2
cells by real-time quantitative PCR and western blot
analysis. As shown, DHC obviously decreased Foxa2
mRNA and protein expression in a dose-dependent
Figure 1 Effect of DHC on apoM expression in HepG2 cells. (A and B) HepG2 cells were divided into four groups and cultured in medium at
37°C containing 0 μM, 25 μM, 50 μM and 100 μM DHC for 24 h, respectively. ApoM transcript levels and protein levels were measured by
real-time quantitative PCR and western blot analysis, respectively. (C and D) HepG2 cells were treated with 100 μM DHC for 0, 6, 12, and24 h,
respectively. ApoM transcript levels and protein levels were measured by real-time quantitative PCR and western blot analysis, respectively. All
results are presented as mean ± SD of three independent experiments, each performed in triplicate. *P < 0.05 vs. the control group.
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Foxa2 siRNA on the down-regulation of apoM which
was induced by DHC. As shown in Figure 2C, In com-
parison to the control siRNA, treatment with siRNA tar-
geting Foxa2 decreased Foxa2 protein expression by 87%
in HepG2 cells. The down-regulation of apoM expres-
sion via DHC treatment was markedly accentated by
Foxa2 siRNA treatment (Figure 2D). Next, we observed
the effects of recombinant plasmids over-expressing
Foxa2 (pcDNA-Foxa2) on apoM expression following
DHC treatment in HepG2 cells. As shown in Figure 2E,
treatment with pcDNA-Foxa2 increased Foxa2 protein
expression by 565% in HepG2 cells. Suppression of
apoM expression by DHC was markedly compensated
by treatment with pcDNA- Foxa2 (Figure 2F).
DHC down-regulates apoM expression through enhancing
LXRα expression in HepG2 cells
The previous study has proved that apoM mRNA levels
were significantly lower in the presence of LXR agonists
in HepG2 cell. A similar reduction was found in vivo.
We next investigated whether LXRα involved in DHC
included down-regulation of apoM. For this purpose, we
performed gene and protein expression of LXRα in
HepG2 cells following treatment with DHC. As shown,
DHC obviously increased LXRα mRNA and protein ex-
pression in a dose-dependent manner (Figure 3A and B).
As shown in Figure 3C, in comparison to the control
siRNA, treatment with siRNA targeting LXRα decreased
LXRα protein expression by 91% in HepG2 cells. The
down-regulation of apoM expression by DHC treatmentwas markedly abolished by LXRα siRNA treatment
(Figure 3D). In addition, we observed the effects of re-
combinant plasmids over-expressing LXRα (pcDNA-
LXRα) on apoM expression following DHC treatment in
HepG2 cells. As shown in Figure 3E, treatment with
pcDNA-LXRα increased LXRα protein expression by
617% in HepG2 cells. Suppression of apoM expression
by DHC was markedly accentated by treatment with
pcDNA-LXRα (Figure 3F).
Effect of DHC on hepatic tissue apoM expression
The liver is the major organ responsible for the produc-
tion and degradation of apoM-containing lipoproteins.
Therefore, we next analyzed the effect of DHC on apoM,
Foxa2 and LXRα expression in the liver of C57BL/6
Mice by western blot analyses. The control and DHC
groups were treated with either vehicle (cholesterol-free
vegetable oil) or with DHC (3.0 mg/kg body weight, dis-
solved in cholesterol-free vegetable oil) daily by oral gav-
age (0.2 mL per mouse) for one weeks and then protein
levels in C57BL/6 Mice liver tissues were investigated by
western blot. As shown (Figure 4), the DHC group had
significantly lower expression of apoM and Foxa2 than
the control group while the DHC group had higher ex-
pression change of LXRα as compared to the control
group.
Discussion
Capsaicinoids, including capsaicin and dihydrocapsaicin,
are the major pungent constituents of ‘hot chilli peppers’
of the Capsicum genus. In addition to food additive uses
Figure 2 Effect of DHC on Foxa2 and expression in HepG2 cells. (A and B) HepG2 cells were divided into four groups and cultured in
medium at 37°C containing 0 μM, 25 μM, 50 μM and 100 μM DHC for 24 h, respectively. Foxa2 transcript levels and protein levels were measured
by real-time quantitative PCR and western blot analysis, respectively. (C) HepG2 cells were transfected with negative control or Foxa2 siRNA.
And then protein samples were measured by western blot analysis. (D) HepG2 cells were transfected with Foxa2 or control siRNA and then
incubated with 100 μM DHC for 24 h. And then protein samples were measured by western blot analysis. (E) HepG2 cells were transfected with
pcDNA3.1-mock (control group) or pcDNA-Foxa2 (pcDNA group). And then protein samples were measured by western blot analysis. (F) HepG2
cells were transfected with pcDNA-Foxa2 or pcDNA-control and then incubated with 100 μM DHC for 24 h. Protein samples were measured by
western blot analysis. All results are presented as mean ± SD of three independent experiments, each performed in triplicate. *P < 0.05 vs. the
control group.
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plications of capsaicin make this compound very popular.
Previous studies have demonstrated that capsaicin is able to
stimulate the release of calcitonin gene-related peptide
(CGRP) by activating transient receptor potential channel
vanilloid type 1 (TRPV1) and therefore it has potential ben-
efits for cardiovascular function [29]. Furthermore, capsaici-
noids can also contribute to their beneficial effects on the
cardiovascular system through their antioxidant properties
[30,31]. Our group have recently shown that DHC can
significantly decrease atherosclerotic plaque formation in-
volving in a PPARγ/LXRα pathway in apoE−/− mice fed a
high-fat/high-cholesterol diet [1]. In the present study, we
demonstrated that apoM expression was regulated by DHC
in HepG2 cells in a dose-dependent and time-dependent
manner and that inhibition of apoM expression by DHC
was mediated by Foxa2 and LXRα.
ApoM is a recently discovered apolipoprotein that is im-
portant for pre-β-HDL formation [32-35]. Overexpression
of apoM in mice increases plasma HDL-cholesterol, and
apoM-deficiency decreases HDL-cholesterol [32]. More-
over, apoM-enrichment of HDL augments the ability of
HDL to mobilize cholesterol from macrophage-derived
foam cells [32,36]. Here, we found that DHC coulddecrease apoM expression through inhibiting Foxa2 expres-
sion and enhancing LXRα expression in HepG2 cells.
ApoM is predominantly associated with HDL (96% is
bound to HDL), but only 5% of the plasma HDL particles
contain an apoM molecule [36]. Although it has been
proved that apoM-deficient led to the appearance of plasma
HDL particles that were larger than those of normal mice,
which impaired in their ability to transport cholesterol out
of macrophages [24], the effect of apoM-deficient on HDL
is limited since just 5% of the plasma HDL particles contain
an apoM molecule. In addition, apoM is a negative acute
response protein that decreases during inflammation. The
level of apoM in mouse serum decreased following LPS ad-
ministration and decrease of its expression in the liver oc-
curs rapidly [37]. Inflammation could increase the risk for
atherosclerosis including alterations in lipid and lipoprotein
metabolism. Besides, HDL isolated during inflammaion is
poorer at removing cholesterol from macrophages than
normal HDL [38]. Zhang et al. showed that high glucose
could inhibit apoM expression in HepG2 cells. Serum
apoM concentrations and hepatic apoM mRNA levels were
significantly reduced in the hyperglycemic rats, indicating
that the low expression levels of apoM in these diabetic ani-
mals could be ascribed to hyperglycemia [20]. Similarly,
Figure 3 Effect of DHC on LXRα and expression in HepG2 cells. (A and B) HepG2 cells were divided into four groups and cultured in
medium at 37uC containing 0 μM, 25 μM, 50 μM and 100 μM DHC for 24 h, respectively. LXRα transcript levels and protein levels were measured
by real-time quantitative PCR and western blot analysis, respectively. (C) HepG2 cells were transfected with negative control or LXRα siRNA. And
then protein samples were measured by western blot analysis. (D) HepG2 cells were transfected with LXRα or control siRNA and then incubated
with 100 μM DHC for 24 h. And then protein samples were measured by western blot analysis. (E) HepG2 cells were transfected with
pcDNA3.1-mock (control group) or pcDNA-LXRα(pcDNA group). And then protein samples were measured by western blot analysis. (F) HepG2
cells were transfected with pcDNA-LXRα or pcDNA-control and then incubated with 100 μM DHC for 24 h. Protein samples were were measured
by western blot analysis. All results are presented as mean ± SD of three independent experiments, each performed in triplicate. *P < 0.05 vs. the
control group.
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compared to controls [19]. These observations suggest that
apoM is link to the development and progression of athero-
sclerosis and diabetes. In the present study, we found that
DHC could decrease apoM expression by inhibiting Foxa2
expression and enhancing LXRα expression in HepG2 cells.
The interesting thing was that our previous study revealed
that DHC could significantly decrease atherosclerotic
plaque formation through enhancing expression of PPARγ
and LXRα in apoE−/− mice fed a high-fat/high-cholesterolFigure 4 Effect of DHC on hepatic apoM, Foxa2 and LXRα expression
group, and treated with either vehicle (cholesterol-free vegetable oil) or DH
protein expression of apoM, Foxa2 and LXRα was measured by western blo
experiments, each performed in triplicate. *P < 0.05 vs. the control group.diet [1]. Here, we demonstrated that DHC could enhance
LXRα expression, which was consistent with our previous
study. However, it is important to consider the inhibition of
apoM expression by DHC when it was used as the thera-
peutic drug for atherosclerosis and diabetes. Thus, more
experiments should be performed to prove DHC might be
potentially used to treat the patients with atherosclerosis
and diabetes.
Foxa2, a key regulator of hepatic lipid metabolism,
which is transcriptionally active in the fasted state and. C57BL/6 Mice were randomized into the control group or the DHC
C (3.0 mg/kg body weight) daily by oral gavage for 1 week. The
t. All results are presented as mean ± SD of three independent
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dation, ketogenesis, and VLDL secretion and bile acid
metabolism, is regulated via insulin/PI3K/Akt-mediated
phosphorylation at a single conserved threonine
(Thr156) residue [39]. Previous studies have shown that
apoM expression and plasma pre-β-HDL levels are de-
creased in obese mice due to inactivation of Foxa2 in
the accompanying hyperinsulinemic state [23]. Treat-
ment of wild-type mice and ob/ob mice with an adeno-
virus containing phosphorylation-defective Foxa2 not
only improved glucose and lipid homeostasis but also in-
creased hepatic apoM mRNA expression. In contrast,
haplo-insufficient Foxa2+/−mice exhibited decreases in
hepatic apoM expression and in plasma pre-β-HDL and
HDL levels. A binding site for Foxa2 in the APOM pro-
moter, at position −474, was identified [24]. In the
present study, we showed that Foxa2 expression was sig-
nificantly decreased by DHC treatment in HepG2 cells.
The down-regulation of apoM expression via DHC treat-
ment was markedly accentated by Foxa2 siRNA treat-
ment. Moreover, the suppression of apoM expression by
DHC was markedly compensated by treatment with
pcDNA-Foxa2. These suggested that Foxa2 was involved
in apoM expression regulation by DHC in HepG2 cells.
LXRα is expressed mainly in the liver, intestine, adipose
tissue and macrophages [27]. LXRs are involved in the
control of major metabolic pathways such as cholesterol
homeostasis, lipogenesis, inflammation and innate immun-
ity [26,40]. Zhang et al. demonstrated that TO901317
downregulates apoM expression in the liver. They showed
that mice treated with 100 mg/kg/d of TO901317 had sig-
nificantly lower apoM plasma levels as compared to control
mice. In cultured HepG2 cells, TO901317 caused a down-
regulation of apoM expression,which was in line with the
in vivo findings [27]. Thus, the agonist significantly de-
creases apoM mRNA expression in vivo and in vitro, indi-
cating that APOM is another target gene of LXR. In the
present study, we showed that the down-regulation of
APOM expression via DHC treatment was markedly abol-
ished by LXRα siRNA treatment. Moreover, the suppres-
sion of apoM expression by DHC was markedly accentated
by treatment with pcDNA-LXRα, suggesting that LXRα is
also involved in apoM expression regulation by DHC in
HepG2 cells.
The liver is the major organ responsible for the produc-
tion and degradation of apoM-containing lipoproteins
[16]. We showed that oral gavage DHC can significantly
decrease expression of apoM. Meanwhile, DHC can mark-
edly decrease expression of Foxa2 than the control group
while increase expression of LXRα as compared to the
control group in the liver of C57BL/6 Mice. In vivo studies
were consistent with the in vitro findings, demonstrating
DHC down-regulates apoM expression through inhibiting
Foxa2 expression and enhancing LXRα expression.Conclusion
Herein, we provided strong evidences that DHC down-
regulates apoM expression through inhibiting Foxa2 ex-
pression and enhancing LXRα expression in HepG2
cells. This research provides a possibility to explain the
molecular mechanism of DHC in down-regulation apoM
expression in hepatic cells. Since DHC has multiple bio-
logical properties and medical applications, it still needs
more experiment evidence to support DHC might be
potentially used to treat the patients with atherosclerosis
and diabetes.
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